PF 6664178

Drug Profile

PF 6664178

Alternative Names: PF-06664178; PF6664178

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 04 May 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV) (Pfizer pipeline, May 2016)
  • 01 Apr 2016 Pfizer terminates a phase I trial for Solid tumours (Late-stage disease) in USA (NCT02122146)
  • 01 Aug 2014 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top